Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SB683699 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| SB683699 | DRUG | - |
Inclusion criteria: * Diagnosis of multiple sclerosis (MS). * Expanded Disability Status Score 0 - 6.5. * One or more relapse of MS in previous 12 months. * Currently not taking any medications for MS (apart from those used to treat symptoms). Exclusion criteria: * Patients with significantly abn...
SB683699 is an investigational small molecule being studied for the treatment of relapsing-remitting multiple sclerosis, a form of multiple sclerosis characterized by episodes of neurologic symptoms followed by periods of remission. It is in Phase 2 clinical development and is not yet approved by regulatory authorities.
SB683699 is being developed by GSK plc, a global biopharmaceutical company traded on the London Stock Exchange under the ticker GSK. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in patients with relapsing-remitting multiple sclerosis.
SB683699 is in Phase 2 clinical development. A Phase 2 trial has been completed, which evaluated the drug in patients with relapsing-remitting multiple sclerosis. The drug remains investigational and has not received regulatory approval for any indication.
SB683699 has been studied in one completed Phase 2 clinical trial, identified as NCT00097331. This trial, titled "Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis," enrolled 261 participants across Belgium, Germany, Poland, Russia, and Spain. The trial was randomized and double-blind.
SB683699 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for relapsing-remitting multiple sclerosis. The completed Phase 2 trial, NCT00097331, has finished, but the drug has not yet received marketing authorization from regulatory agencies.